Effects of heat-inactivated Lactobacillus gasseri TMC0356 on metabolic characteristics and immunity of rats with the metabolic syndrome

British Journal of Nutrition

Volumn 109, Issue 2, 2013, Pages 263-272

  Shi, Lei ^a   Li, Ming ^a   Miyazawa, Kenji ^b   Li, Yun ^a   Hiramatsu, Masaru ^b   Xu, Jiayu ^a   Gong, Cai ^a   Jing, Xiaofan ^a   He, Fang ^b   Huang, Chengyu ^a  

^a SICHUAN UNIVERSITY   (China)

^b Yokohama Kanagawa   (Japan)

Author keywords

Inflammatory immune responses; Lactobacillus gasseri TMC0356; Metabolic syndrome

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INSULIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HIGH SODIUM INTAKE; IMMUNITY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTOBACILLUS GASSERI; LIPID DIET; LYMPHOCYTE; MALE; METABOLIC SYNDROME X; METABOLISM; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; BACTERIAL STRAIN; BODY FAT; CELL COUNT; DRUG MEGADOSE; IMMUNOCOMPETENT CELL; LIPID BLOOD LEVEL; LIVER; LOW DRUG DOSE; SALT INTAKE; THYMUS; WEIGHT GAIN;

ADIPOSITY; ANIMALS; ANTI-OBESITY AGENTS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HOT TEMPERATURE; IMMUNOLOGIC FACTORS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LACTOBACILLUS; LIVER; MALE; METABOLIC SYNDROME X; MICROBIAL VIABILITY; OBESITY; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; THYMUS GLAND;

EID: 84873049936     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S000711451200116X     Document Type: Article

References (42)

1. Alberti KGMM (2005) The metabolic syndrome - a new worldwide definition. Lancet 366, 1059-1062
2. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607
3. Eckel RH, Grundy SM & Zimmet PZ (2005) The metabolic syndrome. Lancet 365, 1415-1428
4. Isomaa B, Almgren P, Tuomi T, et al.(2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689
5. Wilson PWF, D'Agostino RB, Parise H, et al.(2005) Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112, 3066-3072
6. Ford ES, Giles WH & Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359
7. Tillin T, Forouhi N, Johnston D, et al.(2005) Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: A UK population-based cross-sectional study. Diabetologia 48, 649-656
8. Weiss R, Dziura J, Burgert TS, et al.(2004) Obesity and the metabolic syndrome in children and adolescents. New Engl J Med 350, 2362-2374
9. Backhed F, Ley RE, Sonnenburg JL, et al.(2005 Host-bacterial mutualism in the human intestine. Science 307, 1915-1920
10. Cani PD & Delzenne NM (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Design 15, 1546-1558
11. Cani PD & Delzenne NM (2009) Interplay between obesity and associated metabolic disorders: New insights into the gut microbiota. Curr Opin Pharmacol 9, 737-743
12. Ley RE, Turnbaugh PJ, Klein S, et al.(2006) Microbial ecology: Human gut microbes associated with obesity. Nature 444, 1022-1023
13. Ley RE, Backhed F, Turnbaugh P, et al.(2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102, 11070-11075
14. Turnbaugh PJ, Ley RE, Mahowald MA, et al.(2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1131
15. Backhed F, Ding H, Wang T, et al.(2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101, 15718-15723
16. Salminen S, Ouwehand A, Benno Y, et al.(1999) Probiotics: how should they be defined? Trends Food Sci Technol 10, 107-110
17. Goldin BR & Gorbach SL (2008) Clinical indications for probiotics: an overview. Clin Infect Dis 46, Suppl. 2, S96-S100
18. Ishibashi N & Yamazaki S (2001) Probiotics and safety. Am J Clin Nutr 73, 2 Suppl., 465S-470S
19. Ouwehand AC & Salminen SJ (1998) The health effects of cultured milk products with viable and non-viable bacteria. Int Dairy J 8, 749-758
20. He F, Morita H, Kubota A, et al.(2005) Effect of orally administered non-viable Lactobacillus cells on murine humoral immune responses. Microbiol Immunol 49, 993-997
21. Kawase M, He F, Kubota A, et al.(2006) Inhibitory effect of Lactobacillus gasseri TMC0356 and Lactobacillus GG on enhanced vascular permeability of nasal mucosa in experimental allergic rhinitis of rats. Biosci Biotechnol Biochem 70, 3025-3030
22. Kawase M, He F, Kubota A, et al.(2009) Effect of fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in a double-blind placebo-controlled clinical study. Int J Food Microbiol 128, 429-434
23. Naito E, Yoshida Y, Makino K, et al.(2011) Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 110, 650-657
24. Lee HY, Park JH, Seok SH, et al.(2006) Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta 1761, 736-744
25. Tanida M, Shen J, Maeda K, et al.(2008) High-fat diet-induced obesity is attenuated by probiotic strain Lactobacillus paracasei ST11 (NCC2461) in rats. Obes Res Clin Pract 2, 159-169
26. Ohlson K, Mahlapuu M & Svensson U (2007) Probiotics to Influence Fat Metabolism and Obesity. WO Patent WO/2007/043,933
27. Parnell JA & Reimer RA (2009) Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 89, 1751-1759
28. Delzenne NM, Cani PD, Daubioul C, et al.(2007) Impact of inulin and oligofructose on gastrointestinal peptides. Br J Nutr 93, S157-S161
29. Yun S, Park H & Kang J (2009) Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol 107, 1681-1686
30. Tabuchi M, Ozaki M, Tamura A, et al.(2003) Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem 67, 1421-1424
31. Yamano T, Tanida M, Niijima A, et al.(2006) Effects of the probiotic strain Lactobacillus johnsonii strain La1 on autonomic nerves and blood glucose in rats. Life Sci 79, 1963-1967
32. Matsuzaki T, Yamazaki R, Hashimoto S, et al.(1997) Antidiabetic effects of an oral administration of Lactobacillus casei in a non-insulin-dependent diabetes mellitus (NIDDM model using KK-Ay mice. Endocr J 44, 357-365
33. Savransky V, Nanayakkara A, Li J, et al.(2007) Chronic intermittent hypoxia induces atherosclerosis. Am J Resp Crit Care 175, 1290-1297
34. Jakala P & Vapaatalo H (2010) Antihypertensive peptides from milk proteins. Pharmaceuticals 3, 251-272
35. Cani PD, Bibiloni R, Knauf C, et al.(2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470-1481
36. Monteiro R & Azevedo I (2010) Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm (epublication 14 July 2010
37. Erridge C, Attina T, Spickett CM, et al.(2007) A high-fat meal induces low-grade endotoxemia: Evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86, 1286-1292
38. Buettner R, Sch lmerich J & Bollheimer LC (2007) High-fat diets: Modeling the metabolic disorders of human obesity in rodents. Obesity 15, 798-808
39. Morita H, He F, Fuse T, et al.(2002) Cytokine production by the murine macrophage cell line J774. 1 after exposure to lactobacilli. Biosci Biotechnol Biochem 66, 1963-1966
40. Suganami T & Ogawa Y (2010) Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 88, 33-39
41. Miettinen M, Vuopio-Varkila J & Varkila K (1996) Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 64, 5403-5405
42. Erickson KL & Hubbard NE (2000) Probiotic immunomodulation in health and disease. J Nutr 130, 2S Suppl., 403S-409S.